<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097742</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0638</org_study_id>
    <nct_id>NCT05097742</nct_id>
  </id_info>
  <brief_title>Cognitive Impairments in Children With Epilepsy</brief_title>
  <official_title>Interest of Speech Therapy in Children With Epilepsy: What Impairments of Cognitive Functions?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the proportion of language and attentional difficulties in patients with epilepsy is&#xD;
      recognized, both in the literature and in the clinical experience of practitioners, it is&#xD;
      appropriate to propose a complete speech-language assessment of oral language and&#xD;
      attention.This study investigates these impairments through the taking of specific tests.&#xD;
&#xD;
      The general objective of this study is to observe possible oral language and attention&#xD;
      disorders in children with epilepsy, by age and etiology of epilepsy.&#xD;
&#xD;
      The objective of this work is to study therapeutic apheresis (including plasma exchange and&#xD;
      immunoadsorption) among french neuropediatric tertiary centers and to prove that this&#xD;
      treatment modality is effective and well tolerated in pediatric neurology diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score in the different tests assessing oral language</measure>
    <time_frame>day 1</time_frame>
    <description>Test assessing oral language :&#xD;
Oral naming of images&#xD;
Oral designation of images&#xD;
Morphosyntactic comprehension test&#xD;
Syntactic production test&#xD;
The scores obtained in the various tests are organized into 7 classes:&#xD;
Class 1 = percentiles less than 7 : &quot;pathological&quot; zone Class 2 = 7 to 20 percentiles : &quot;fragile&quot; zone / &quot;weak&quot; zone Class 3 = 21 to 38 percentiles : &quot;low standard&quot; zone Class 4 = percentiles 39 to 62 : &quot;median standard&quot; zone / expected average results for age or grade level Class 5 = 63 to 80 percentiles : &quot;higher standard&quot; zone Classes 6 and 7 = respectively 81 to 93 percentiles and percentiles greater than 93 : zone with results well above the norm for age or grade level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score in the different tests assessing attention</measure>
    <time_frame>day 1</time_frame>
    <description>Tests assessing attention :&#xD;
Visual attention test&#xD;
Auditive attention test&#xD;
The scores obtained in the various tests are organized into 7 classes:&#xD;
Class 1 = percentiles less than 7 : &quot;pathological&quot; zone Class 2 = 7 to 20 percentiles : &quot;fragile&quot; zone / &quot;weak&quot; zone Class 3 = 21 to 38 percentiles : &quot;low standard&quot; zone Class 4 = percentiles 39 to 62 : &quot;median standard&quot; zone / expected average results for age or grade level Class 5 = 63 to 80 percentiles : &quot;higher standard&quot; zone Classes 6 and 7 = respectively 81 to 93 percentiles and percentiles greater than 93 : zone with results well above the norm for age or grade level.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Epilepsy Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Children with epilepsy followed by Dr COLMARD at the Montpellier hospital and university&#xD;
        center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        The subjects should :&#xD;
&#xD;
          -  Be at least 3 years old and at most 15 years old&#xD;
&#xD;
          -  Be French speaker&#xD;
&#xD;
          -  Be in a regular class&#xD;
&#xD;
          -  Have a diagnosis of epilepsy&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subjects schooled in IEM&#xD;
&#xD;
          -  Subjects diagnosed with austim spectrum disorder&#xD;
&#xD;
          -  Subjects with a motor or visual handicap&#xD;
&#xD;
          -  Subjects with psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime colmard, r√©sident</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moritz-Gasser Sylvie</last_name>
    <role>Study Chair</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucile Lascombe, manager</last_name>
    <phone>668992318</phone>
    <phone_ext>33</phone_ext>
    <email>Lascombe.lucile@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maxime colmard, MD</last_name>
    <phone>672646907</phone>
    <phone_ext>33</phone_ext>
    <email>m-colmard@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magalie Vicedomini</last_name>
      <phone>680424920</phone>
      <phone_ext>33</phone_ext>
      <email>Magalie.orthophonie@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lucile Lascombe</last_name>
      <phone>668992318</phone>
      <phone_ext>33</phone_ext>
      <email>Lascombe.lucile@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Speech therapy</keyword>
  <keyword>Neurology</keyword>
  <keyword>Children</keyword>
  <keyword>Oral language</keyword>
  <keyword>Attention</keyword>
  <keyword>Type of epilepsy (focal epilepsy or generalized epilepsy)</keyword>
  <keyword>Etiology of epilepsy (unknown, idiopathic, structural, metabolic, immune, infectious)</keyword>
  <keyword>Epilepsy syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epileptic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

